1-3 of 3
John R. Murren
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer

Gregory A. Otterson, Miguel A. Villalona-Calero, William Hicks, Xueliang Pan, John A. Ellerton, Scott N. Gettinger, John R. Murren
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2466–2473.
https://doi.org/10.1158/1078-0432.CCR-09-3015
Published: 14 April 2010
View article titled, Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs

Gregory A. Otterson, Miguel A. Villalona-Calero, Sunil Sharma, Mark G. Kris, Anthony Imondi, Mirjam Gerber, Dorothy A. White, Mark J. Ratain, Joan H. Schiller, Alan Sandler, Michael Kraut, Sridhar Mani, John R. Murren
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1246–1252.
https://doi.org/10.1158/1078-0432.CCR-06-1096
Published: 22 February 2007
View article titled, Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs
Open the PDF for Phase I Study of Inhaled Doxorubicin for Patients with Metastatic Tumors to the Lungs in another window
Journal Articles

Modulating Multidrug Resistance: Can We Target this Therapy?

John R. Murren
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 633–635.
Published: 01 March 2002
View article titled, Modulating Multidrug Resistance: <subtitle>Can We Target this Therapy?</subtitle>
Open the PDF for Modulating Multidrug Resistance: <subtitle>Can We Target this Therapy?</subtitle> in another window